Early Access and Managed Entry Agreements in Europe
23.09.2017 07:02
Accelerated market access - Which programmes and methods fit? Get the latest information at this seminar.
Termindetails
Wann
19.02.2017
von 09:10 bis 17:10
von 09:10 bis 17:10
Wo
Frankfurt
Kontakttelefon
+49 6221 500-680
Teilnehmer
This seminar addresses the needs of pharmaceutical industry employees in medical affairs, market access and healthcare management.
Those dealing with market access strategies within Europe will especially benefit from this seminar.
Those dealing with market access strategies within Europe will especially benefit from this seminar.
This seminar provides you with a detailed overview of early access possibilities in the EU in general as well as in Germany, the UK, Ireland, Spain and France in particular.
After having attended the seminar, you will be aware of the available options for, and the arising challenges of, bringing your pharmaceuticals to the European market as fast as possible.
Specifically, topics such as eligibility to the various programmes, data requirements and reimbursement options will be discussed in order to acquire a deep understanding of how patients could benefit from your products at the earliest possible.
After having attended the seminar, you will be aware of the available options for, and the arising challenges of, bringing your pharmaceuticals to the European market as fast as possible.
Specifically, topics such as eligibility to the various programmes, data requirements and reimbursement options will be discussed in order to acquire a deep understanding of how patients could benefit from your products at the earliest possible.
Themen der Veranstaltung:
- Early access and accelerated access programmes at the EU level
- Unmet medical need: compassionate use and off-label use
- Market access via managed entry agreements
- Possibilities at a national level in France, Germany, Spain, the UK and Ireland
- Pricing: reimbursement in early access programmes
- Unmet medical need: compassionate use and off-label use
- Market access via managed entry agreements
- Possibilities at a national level in France, Germany, Spain, the UK and Ireland
- Pricing: reimbursement in early access programmes
